摘要
目的研究消胀方联合拉米夫定对代偿期乙型肝炎肝硬化患者肝功能、血清肝纤维化指标及肝脏硬度值的影响。方法将70例代偿期乙型肝炎肝硬化患者随机分为治疗组和对照组,各35例。对照组予扶正化瘀胶囊联合拉米夫定治疗,治疗组予消胀方联合拉米夫定治疗,2组均治疗12月。治疗前后比较2组的肝功能、血清肝纤维化指标及肝脏硬度值,并观察2组不良反应发生情况。结果治疗后2组血清肝纤维化指标及肝脏硬度值均明显降低,肝功能指标明显改善,与同组治疗前比较差异均有统计学意义(P<0.05),且治疗组改善程度明显优于对照组(P<0.05);2组在治疗过程中均未发生明显不良反应。结论消胀方联合拉米夫定能明显改善代偿期乙型肝炎肝硬化患者的肝功能及肝脏纤维化程度,且无明显不良反应,值得在临床上推广运用。
Objective To observe the effect of Xiaozhang Fang combined with lamivudine on liver function and liver fibrosis degree in patients with hepatitis B virus-related compensated cirrhosis. Methods 70 patients with hepatitis B virus-related compensated cirrhosis were divided into two groups（ 35 cases in each group）. The control group was given Fuzheng Huayu Capsules combined with lamivudine,but the treatment group was given Xiaozhang Fang combined with lamivudine. Both were treated for 12 months. Then,liver function and liver fibrosis index in serum as well as liver hardness number were compared between two groups before and after treatment,and the adverse effects were observed. Results After treatment,liver fibrosis index in serum and liver hardness number of the two groups both dropped noticeably,and liver function index improved significantly. The differences before and after treatment were significant（ P〈0. 05）,and the reduction was more in treatment group than in control group（ P〈0.05）.There were no adverse effects in two groups. Conclusion Xiaozhang Fang combined with lamivudine can improve the liver function and liver fibrosis degree in patients with hepatitis B virus-related compensated cirrhosis without obvious adverse effects,which is worthy of clinical promotion and application.
作者
徐彤
甘霞
袁今奇
XU Tong;GAN Xia;YUAN Jinqi(Department of Chinese Medicine,the First Affiliated Hospital of Clinical College of Medicine,Shihezi University,Shihezi,Xinjiang,832008,China)
出处
《甘肃中医药大学学报》
2018年第4期53-56,共4页
Journal of Gansu University of Chinese Medicine
基金
国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教发[2014]20号)
关键词
代偿期乙型肝炎肝硬化
消胀方
拉米夫定
肝功能
肝纤维化
肝脏硬度值
临床观察
hepatitis B virus-related compensated cirrhosis
Xiaozhang Fang
lamivudine
liver function
liverfibrosis
liver hardness number
clinical observation
